St. Jude Warning Letter Adds More Pressure On Firm’s Leads Division

The company stresses that FDA’s letter does not identify any specific concerns about Durata or any other product, but the citation nonetheless states that the leads are “adulterated” due to quality system violations and “misbranded” due to adverse event reporting lapses.

More from Archive

More from Medtech Insight